Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
111
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
111
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
2020-11-13 14:51 | Report Abuse
Assuming that the Perikatan Nasional coalition wins the election and returns to power with a fresh mandate, it could reintroduce GST during the budget announcement in November, with implementation to take place between mid-2021 and early 2022.
Stock
Stock
2020-11-13 10:09 | Report Abuse
loan moratorium on the way
Stock
2020-11-13 09:35 | Report Abuse
heard got some contracts announcing next week
Stock
2020-11-09 20:09 | Report Abuse
Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection
Stock
Stock
Stock
Stock
2020-11-09 20:04 | Report Abuse
Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection
Stock
Stock
Stock
Stock
Stock
2020-11-06 17:57 | Report Abuse
Top Glove - 150m
Hartalega - 150m
Supermax - 50m
Kossan - 50m
Stock
2020-11-06 17:55 | Report Abuse
400m must divide by capacity
Stock
Stock
Stock
Stock
Stock
2020-10-27 16:51 | Report Abuse
thanks ECL..still have faith in you
Stock
Stock
2020-10-23 14:27 | Report Abuse
LTLK supporters coming to promote soon
Stock
Stock
2020-10-22 14:02 | Report Abuse
RIO DE JANEIRO: A volunteer participating in clinical trials of the COVID-19 vaccine developed by Oxford University and AstraZeneca has died in Brazil, officials announced on Wednesday (Oct 21), though media reports said he had received a placebo, not the test vaccine.
you guys know what is a placebo right?
Stock
Stock
2020-10-21 12:02 | Report Abuse
sell first, come back at 7+
Stock
2020-10-21 11:56 | Report Abuse
panic selling ! buy back later
Stock
2020-10-18 13:17 | Report Abuse
OUR SCIENCE/ An Open Letter from Pfizer Chairman and CEO Albert Bourla
October 16, 2020
As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing their hopes in a safe and effective COVID-19 vaccine to overcome this pandemic. I know there is a great deal of confusion regarding exactly what it will take to ensure its development and approval, and given the critical public health considerations and the importance of transparency, I would like to provide greater clarity around the development timelines for Pfizer’s and our partner BioNTech’s COVID-19 vaccine.
There are three key areas where, as with all vaccines, we must demonstrate success in order to seek approval for public use. First, the vaccine must be proven effective, meaning it can help prevent COVID-19 disease in at least a majority of vaccinated patients. Second and equally important, the vaccine must be proven safe, with robust safety data generated from thousands of patients. And finally, we must demonstrate that the vaccine can be consistently manufactured at the highest quality standards.
To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines for each of these three areas.
As I’ve said before, we are operating at the speed of science. This means we may know whether or not our vaccine is effective by the end of October. To do so, we must accumulate a certain number of COVID-19 cases in our trial to compare the effectiveness of the vaccine in vaccinated individuals to those who received a placebo. Since we must wait for a certain number of cases to occur, this data may come earlier or later based on changes in the infection rates. As Pfizer is blinded to who received the vaccine versus the placebo, a committee of independent scientists will review the complete data and they will inform us if the vaccine is effective or not based on predetermined criteria at key interim analysis points throughout the trial. Pfizer will continue running the trial through its final analysis point even if it is declared effective at an earlier stage. In the spirit of candor, we will share any conclusive readout (positive or negative) with the public as soon as practical, usually a few days after the independent scientists notify us.
A key point that I’d like to make clear is that effectiveness would satisfy only one of the three requirements and, alone, would not be enough for us to apply for approval for public use.
The second requirement is to prove that the vaccine is safe. Our internal standards for vaccine safety and those required by regulators are set high. In the instance of Emergency Use Authorization in the U.S. for a potential COVID-19 vaccine, FDA is requiring that companies provide two months of safety data on half of the trial participants following the final dose of the vaccine. Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November. Safety is, and will remain, our number one priority, and we will continue monitoring and reporting safety data for all trial participants for two years.
And finally, if we achieve a positive efficacy readout and a robust safety profile, the last requirement will be the submission of manufacturing data that demonstrates the quality and consistency of the vaccine that will be produced. Pfizer has been investing at risk since the early days of the pandemic to perfect our manufacturing processes and rapidly build up capacity. We expect to have our manufacturing data ready for submission before the safety milestone is reached.
So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November. All the data contained in our U.S. application would be reviewed not only by the FDA’s own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency.
The timelines above reflect our best estimates of when these important milestones could be achieved. For 171 years Pfizer has been known for our high-quality standards. Our purpose is to discover breakthroughs that change patients’ lives. I cannot think of a breakthrough that would be more meaningful to a greater number of people than an effective and safe COVID-19 vaccine.
In the meantime, I hope you and your loved ones are staying safe and well.
Stock
2020-10-18 13:17 | Report Abuse
OUR SCIENCE/ An Open Letter from Pfizer Chairman and CEO Albert Bourla
October 16, 2020
As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing their hopes in a safe and effective COVID-19 vaccine to overcome this pandemic. I know there is a great deal of confusion regarding exactly what it will take to ensure its development and approval, and given the critical public health considerations and the importance of transparency, I would like to provide greater clarity around the development timelines for Pfizer’s and our partner BioNTech’s COVID-19 vaccine.
There are three key areas where, as with all vaccines, we must demonstrate success in order to seek approval for public use. First, the vaccine must be proven effective, meaning it can help prevent COVID-19 disease in at least a majority of vaccinated patients. Second and equally important, the vaccine must be proven safe, with robust safety data generated from thousands of patients. And finally, we must demonstrate that the vaccine can be consistently manufactured at the highest quality standards.
To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines for each of these three areas.
As I’ve said before, we are operating at the speed of science. This means we may know whether or not our vaccine is effective by the end of October. To do so, we must accumulate a certain number of COVID-19 cases in our trial to compare the effectiveness of the vaccine in vaccinated individuals to those who received a placebo. Since we must wait for a certain number of cases to occur, this data may come earlier or later based on changes in the infection rates. As Pfizer is blinded to who received the vaccine versus the placebo, a committee of independent scientists will review the complete data and they will inform us if the vaccine is effective or not based on predetermined criteria at key interim analysis points throughout the trial. Pfizer will continue running the trial through its final analysis point even if it is declared effective at an earlier stage. In the spirit of candor, we will share any conclusive readout (positive or negative) with the public as soon as practical, usually a few days after the independent scientists notify us.
A key point that I’d like to make clear is that effectiveness would satisfy only one of the three requirements and, alone, would not be enough for us to apply for approval for public use.
The second requirement is to prove that the vaccine is safe. Our internal standards for vaccine safety and those required by regulators are set high. In the instance of Emergency Use Authorization in the U.S. for a potential COVID-19 vaccine, FDA is requiring that companies provide two months of safety data on half of the trial participants following the final dose of the vaccine. Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November. Safety is, and will remain, our number one priority, and we will continue monitoring and reporting safety data for all trial participants for two years.
And finally, if we achieve a positive efficacy readout and a robust safety profile, the last requirement will be the submission of manufacturing data that demonstrates the quality and consistency of the vaccine that will be produced. Pfizer has been investing at risk since the early days of the pandemic to perfect our manufacturing processes and rapidly build up capacity. We expect to have our manufacturing data ready for submission before the safety milestone is reached.
So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November. All the data contained in our U.S. application would be reviewed not only by the FDA’s own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency.
The timelines above reflect our best estimates of when these important milestones could be achieved. For 171 years Pfizer has been known for our high-quality standards. Our purpose is to discover breakthroughs that change patients’ lives. I cannot think of a breakthrough that would be more meaningful to a greater number of people than an effective and safe COVID-19 vaccine.
In the meantime, I hope you and your loved ones are staying safe and well.
Stock
2020-10-14 16:20 | Report Abuse
Wednesday, October 14, 2020
China carries out 4.2 million tests in Qingdao
China has said it carried out more than 4.2 million tests in the northern port city of Qingdao, with no new cases of coronavirus found among the almost 2 million sets of results received.
The city has reported a total of 12 cases, six with symptoms and six without, since the new outbreak was first spotted over the weekend at a hospital.
China reported 27 new cases of coronavirus, including 13 new cases of local transmission and 14 cases brought from outside the country. The local cases included seven that had been shifted to confirmed from asymptomatic.
It wasn’t immediately clear whether any of those involved cases reported in Qingdao.
Stock
2020-10-14 16:19 | Report Abuse
mighty China also facing a resurgence
Stock
2020-10-14 16:19 | Report Abuse
Wednesday, October 14, 2020
China carries out 4.2 million tests in Qingdao
China has said it carried out more than 4.2 million tests in the northern port city of Qingdao, with no new cases of coronavirus found among the almost 2 million sets of results received.
The city has reported a total of 12 cases, six with symptoms and six without, since the new outbreak was first spotted over the weekend at a hospital.
China reported 27 new cases of coronavirus, including 13 new cases of local transmission and 14 cases brought from outside the country. The local cases included seven that had been shifted to confirmed from asymptomatic.
It wasn’t immediately clear whether any of those involved cases reported in Qingdao.
Stock
Stock
Stock
Stock
2020-10-09 14:24 | Report Abuse
last chance on the supermx train
Stock
2020-10-08 20:15 | Report Abuse
OTB has spoken, time to flyyyy
Stock
Stock
2020-10-07 14:50 | Report Abuse
The White House shared rules for staff interacting with the infected president. In an email seen by the New York Times, White House staff were told to go to the second floor, where Trump is being treated, only if required. If there, those who had to go within six feet of the president were to wear gowns, surgical masks, eyewear and gloves.
have to wear gloves..
Stock
2020-10-07 14:50 | Report Abuse
The White House shared rules for staff interacting with the infected president. In an email seen by the New York Times, White House staff were told to go to the second floor, where Trump is being treated, only if required. If there, those who had to go within six feet of the president were to wear gowns, surgical masks, eyewear and gloves.
have to wear gloves..
Stock
Stock
2020-10-06 22:55 | Report Abuse
GENEVA (Reuters) - A vaccine against COVID-19 may be ready by year-end, the head of the World Health Organization (WHO) said on Tuesday, without elaborating.
WHO Director-General Tedros Adhanom Ghebreyesus, addressing the end of a two-day meeting of its Executive Board on the pandemic, said: "We will need vaccines and there is hope that by the end of this year we may have a vaccine. There is hope."
Nine experimental vaccines are in the pipeline of the WHO-led COVAX global vaccine facility that aims to distribute 2 billion doses by the end of 2021.
Stock
Stock
Stock
2020-10-06 17:49 | Report Abuse
If you have not made a few hundred percent profit from equity investment in the last 6 months, you must change your stock selection method and read this article carefully to know your mistakes.
Almost every day, I receive buy recommendations of some stocks or ask for my opinion of some stocks or to participate in pre-IPO venture. For example; Property Developer Hil Industry Bhd. which has a unit called Hil Medic has received approval from the Ministry of Health for the manufacture of face masks and face shields.
A few days ago, someone recommended Prolexus, selling 90 sen and reported a big jump in EPS for its latest quarter of 13 sen from making face masks. Naturally the price has been shooting up higher and higher. Prolexus has been losing money in the last 2 quarters. I doubt Prolexus and Hil Medic can make face masks cheaper than those manufacturers from China, Vietnam, Cambodia and Thailand etc.
To be courteous I have to spend some time to check and respond. My purpose of writing this piece is to save your time and my time so that we can take advantage of this rare opportunity to make a lot of money.
The current Covid19 pandemic has been affecting everyone’s movement, all businesses, listed and non-listed companies with the exception of medical gloves and medical products for the virus prevention. As a result, the demand for gloves far exceeds supply and all the glove manufacturers are increasing their selling prices continuously to make more and more profit which are being reflected on their share prices. That is why each of the glove stocks has shot up a few hundred percent in the last 6 months.
I know for sure all the Investment Banks including EPF are losing money because each of them has bought a big basket of stocks before the pandemic. They would have bought stocks in Airlines, Properties, Constructions, Technologies, manufactures of some products etc.
More gloves are required when vaccines are made available
Many investors of glove stocks have started to sell their holdings in view of the discovery of the vaccine for the virus prevention. Many scientists predicted the pandemic will take a few years to disappear. When enough of vaccines is made available to vaccinate 75% of the people in the world to prevent the spread of the virus, more medical workers would be required and all of them would require gloves. Moreover, it will take a long time to produce so much of vaccines and to vaccinate so many people.
Obviously, the demand for gloves will continue to exceeds supply for a long time. If you have not been making money in the last 6 months, you must use all your funds to buy glove stocks and not on any other stocks.
The best stock to buy is Supermax because it has the best profit growth rate as reported in its last few quarters. That is why its share price has been shooting up faster than Top Glove or any other glove stocks as shown on their price charts for the last 6 months.
Stock
2020-10-06 16:39 | Report Abuse
If you have not made a few hundred percent profit from equity investment in the last 6 months, you must change your stock selection method and read this article carefully to know your mistakes.
Almost every day, I receive buy recommendations of some stocks or ask for my opinion of some stocks or to participate in pre-IPO venture. For example; Property Developer Hil Industry Bhd. which has a unit called Hil Medic has received approval from the Ministry of Health for the manufacture of face masks and face shields.
A few days ago, someone recommended Prolexus, selling 90 sen and reported a big jump in EPS for its latest quarter of 13 sen from making face masks. Naturally the price has been shooting up higher and higher. Prolexus has been losing money in the last 2 quarters. I doubt Prolexus and Hil Medic can make face masks cheaper than those manufacturers from China, Vietnam, Cambodia and Thailand etc.
To be courteous I have to spend some time to check and respond. My purpose of writing this piece is to save your time and my time so that we can take advantage of this rare opportunity to make a lot of money.
The current Covid19 pandemic has been affecting everyone’s movement, all businesses, listed and non-listed companies with the exception of medical gloves and medical products for the virus prevention. As a result, the demand for gloves far exceeds supply and all the glove manufacturers are increasing their selling prices continuously to make more and more profit which are being reflected on their share prices. That is why each of the glove stocks has shot up a few hundred percent in the last 6 months.
I know for sure all the Investment Banks including EPF are losing money because each of them has bought a big basket of stocks before the pandemic. They would have bought stocks in Airlines, Properties, Constructions, Technologies, manufactures of some products etc.
More gloves are required when vaccines are made available
Many investors of glove stocks have started to sell their holdings in view of the discovery of the vaccine for the virus prevention. Many scientists predicted the pandemic will take a few years to disappear. When enough of vaccines is made available to vaccinate 75% of the people in the world to prevent the spread of the virus, more medical workers would be required and all of them would require gloves. Moreover, it will take a long time to produce so much of vaccines and to vaccinate so many people.
Obviously, the demand for gloves will continue to exceeds supply for a long time. If you have not been making money in the last 6 months, you must use all your funds to buy glove stocks and not on any other stocks.
The best stock to buy is Supermax because it has the best profit growth rate as reported in its last few quarters. That is why its share price has been shooting up faster than Top Glove or any other glove stocks as shown on their price charts for the last 6 months.
Stock
2020-10-06 16:38 | Report Abuse
If you have not made a few hundred percent profit from equity investment in the last 6 months, you must change your stock selection method and read this article carefully to know your mistakes.
Almost every day, I receive buy recommendations of some stocks or ask for my opinion of some stocks or to participate in pre-IPO venture. For example; Property Developer Hil Industry Bhd. which has a unit called Hil Medic has received approval from the Ministry of Health for the manufacture of face masks and face shields.
A few days ago, someone recommended Prolexus, selling 90 sen and reported a big jump in EPS for its latest quarter of 13 sen from making face masks. Naturally the price has been shooting up higher and higher. Prolexus has been losing money in the last 2 quarters. I doubt Prolexus and Hil Medic can make face masks cheaper than those manufacturers from China, Vietnam, Cambodia and Thailand etc.
To be courteous I have to spend some time to check and respond. My purpose of writing this piece is to save your time and my time so that we can take advantage of this rare opportunity to make a lot of money.
The current Covid19 pandemic has been affecting everyone’s movement, all businesses, listed and non-listed companies with the exception of medical gloves and medical products for the virus prevention. As a result, the demand for gloves far exceeds supply and all the glove manufacturers are increasing their selling prices continuously to make more and more profit which are being reflected on their share prices. That is why each of the glove stocks has shot up a few hundred percent in the last 6 months.
I know for sure all the Investment Banks including EPF are losing money because each of them has bought a big basket of stocks before the pandemic. They would have bought stocks in Airlines, Properties, Constructions, Technologies, manufactures of some products etc.
More gloves are required when vaccines are made available
Many investors of glove stocks have started to sell their holdings in view of the discovery of the vaccine for the virus prevention. Many scientists predicted the pandemic will take a few years to disappear. When enough of vaccines is made available to vaccinate 75% of the people in the world to prevent the spread of the virus, more medical workers would be required and all of them would require gloves. Moreover, it will take a long time to produce so much of vaccines and to vaccinate so many people.
Obviously, the demand for gloves will continue to exceeds supply for a long time. If you have not been making money in the last 6 months, you must use all your funds to buy glove stocks and not on any other stocks.
The best stock to buy is Supermax because it has the best profit growth rate as reported in its last few quarters. That is why its share price has been shooting up faster than Top Glove or any other glove stocks as shown on their price charts for the last 6 months.
Stock
2020-10-06 16:29 | Report Abuse
only stocks to buy now is healthcare related..
Stock
Stock: [IFCAMSC]: IFCA MSC BHD
2020-11-13 15:16 | Report Abuse
SOME two years ago, IFCA MSC Bhd was an investor favourite and widely seen as a prime beneficiary of the implementation of the Goods and Services Tax (GST).
Its share price hit an all-time high of RM1.77 on May 18, 2015, giving it a market capitalisation of RM1.012 billion and making it the world’s top-performing software company that year.
Back then, investors were expecting the ACE Market-listed company’s financial years ended Dec 31, 2014 (FY2014) and FY2015 to be bumper years as domestic property developers needed to upgrade their internal business and accounting systems and install GST software ahead of the new tax regime.